metabolic disease

08.11.2024 • News

Ascendis Licences Proprietary Technology to Novo Nordisk

Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop, manufacture, and commercialize proprietary products for the treatment of metabolic and cardiovascular diseases.

11.05.2016 • News

Pfizer and Wave Life Sciences in Metabolic Diseases Pact

08.11.2015 • News

AstraZeneca to buy ZS Pharma for $2.7 billion

Top-Feature

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.